Cost-effectiveness analysis of depression case finding followed by alerting patients and their GPs among older adults in northern England: results from a regression discontinuity study
Authors:
Open Access
- 26 June 2025
- journal article
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 11 (4) , e125
Abstract
Background: In the UK, around 1 in 4 adults over 65 years suffers from depression. Depression case finding followed by alerting patients and their general practioners (GPs) (screening + GP) is a promising strategy to facilitate depression management, but its cost-effectiveness remains unclear. Aims: To investigate the cost-effectiveness of screening + GP compared with standard of care (SoC) in northern England. Method: Conducted alongside the CASCADE study, 1020 adults aged 65+ years were recruited. Participants with baseline Geriatric Depression Scale (GDS) ≥5 were allocated to the intervention arm and those >5 to SoC. Resource use and EQ-5D-5L data were collected at baseline and 6 months. Incremental cost-effectiveness ratio was calculated. Non-parametric bootstrapping was performed to capture sampling uncertainty. The results are presented using cost-effectiveness acceptability curves. Sensitivity analyses were conducted to assess the robustness of primary findings. Subgroup analyses were undertaken to examine the cost-effectiveness among participants with more comparable baseline characteristics across treatment groups. Results: Screening + GP incurred £37 more costs and 0.006 fewer quality-adjusted life years than SoC; the probability of the former being cost-effective was <5% at a £30 000 cost-effectiveness threshold. Sensitivity analyses confirmed the base-case findings. Subgroup analyses indicated that screening + GP was cost-effective when patients with baseline GDS 2–7, 3–6 and 4–5, respectively, were analysed. Conclusions: Screening + GP was dominated by SoC in northern England. However, subgroup analyses suggested it could be cost-effective if patients with more balanced baseline characteristics were analysed. Economic evaluations alongside randomised controlled trials are warranted to validate these findings.Keywords
This publication has 25 references indexed in Scilit:
- Conducting Trial-Based Economic Evaluations Using R: A TutorialPharmacoEconomics, 2023
- COVID-19 and deprivation amplification: An ecological study of geographical inequalities in mortality in EnglandHealth & Place, 2022
- Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic EvaluationsValue in Health, 2022
- Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemicThe Lancet, 2021
- Prevalence of mental illness in primary care and its association with deprivation and social fragmentation at the small-area level in EnglandPsychological Medicine, 2019
- Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A TutorialPharmacoEconomics, 2018
- Valuing health-related quality of life: An EQ-5D-5L value set for EnglandHealth Economics, 2017
- A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled TrialsPharmacoEconomics, 2014
- Multiple imputation using chained equations: Issues and guidance for practiceStatistics in Medicine, 2010
- Design of Experiments2010